Glucose-enriched, racemic lactate buffered solutions for peritoneal dialysis induce a significant reduction of cell viability as well as a hypertrophic, senescent phenotype of the exposed monolayer. The present study was designed to verify whether the aforementioned changes resulted form the buffer, from the osmotic agent, or from a combined effect of both. Mice were acutely (2 h) and long-term (15 and 30 days) exposed to daily intraperitoneal injections of a racemic lactate, heat-sterilized, low-pH (5.2), glucose-free solution. Imprints of the monolayer were taken at the end of each time interval. The glucose-free lactated buffer used in the present study did not induce significant changes in density distribution, mean cell size, mean cytoplasmic surface area, prevalence of large cells, multinucleation, proportion of observed cells in mitosis, and cell viability. So far, the previously mentioned hypertrophic phenotype appears to derive from substantial alterations in the cell cycle of mesothelium exposed to high concentrations of glucose and/or advanced glycosylation end products and unrelated to lactate.

Keywords:
Buffers, Lactate, Peritoneal dialysis, Peritoneal dialysis fluids, biocompatibility, Population analysis of mesothelium
1.
Due AK, Vas SI, Weatherhead JE: Effects of the composition of peritoneal dialysis fluid on chemiluminescence, phagocytosis, and bactericidal activity in vitro. Infect Immun 1981;33:130–135.
2.
Gagnon RF, Obst G, Richards GK, Gervais F: Effect of drug additives to peritoneal dialysis solutions on the viability and function of mouse peritoneal cells. Nephron 1990;56:201–205.
3.
Van Bronswijk H, Verbrough HA, Bos HJ, Heezius ECJM, Oe PL, Van der Muelan J, Verhoef J: Cytotoxic effects of commercial continuous ambulatory peritoneal dialysis (CAPD) fluids and of bacterial exoproducts on human mesothelial cells in vitro. Perit Dial Int 1989;9:197–202.
4.
Topley N, Mackenzie R, Petersen MM, Beavis MJ, Williams D, Thomas N, Faict D, Peluso F, Coles GA, Davies M, Williams JD: In vitro testing of a potentially biocompatible continuous ambulatory peritoneal dialysis fluid. Nephrol Dial Transplant 1991;6:574–581.
5.
Witowski J, Topley N, Jorres A, Liberek T, Coles GA, Williams JD: Effect of lactate-buffered peritoneal dialysis fluids on human peritoneal mesothelial cell interleukin-6 and prostaglandin synthesis. Kidney Int 1995;47:282–293.
6.
Breborowicz A: In vitro study on the biocompatibility of the peritoneal dialysis solution. Perit Dial Int 1993;13(suppl 2):105–108.
7.
Breborowicz A, Rodela H, Martis L, Oreopoulos DG: Lactate at acid pH is responsible for the decrease in intracellular glutathione (GSH) of mesothelial cells (MC) exposed to dialysis solutions: Perit Dial Int 1995;15(suppl 1):68.
8.
Shostak A, Pivnik E, Gotloib L: Cultured rat mesothelial cells generate hydrogen peroxide: A new player in peritoneal defense? J Am Soc Nephrol 1996;7:2371–2378.
9.
Shostak A, Pivnik E, Gotloib L: Daily short exposure of cultured mesothelial cells to lactated, high glucose, low pH fluid induces a low profile regenerative steady state. Nephrol Dial Transplant 1996;11:608–613.
10.
Fresheny RI: Animal Cell Culture. Oxford, IRL Press, 1989, p 44.
11.
Passlick-Deetjen J: The importance of biocompatibility in peritoneal dialysis solutions. Perit Dial Int 1993;13(suppl 2):101–104.
12.
Holmes CK: Biocompatibility of peritoneal dialysis solutions. Perit Dial Int 1993;13:88–94.
13.
Breborowicz A, Balaskas E, Oreopoulos GD, Markis L, Serkes K, Oreopoulos DG: In vitro study of the effect of osmotic solutes on the interactions between cells from the peritoneum and peritoneal cavity. Perit Dial Int 1994;14:149–154.
14.
Topley N: What is the ideal technique for testing the biocompatibility of peritoneal dialysis solutions. Perit Dial Int 1995;15:205–209.
15.
Gotloib L, Shostak A, Wajsbrot V, Kushnier R: Biocompatibility of dialysis solutions evaluated by histochemical techniques applied to mesothelial cell imprints. Perit Dial Int 1993;13(suppl 2):113–115.
16.
Gotloib L, Shostak A, Wajsbrot V, Kushnier R: The cytochemical profile of visceral hyperosmolar peritoneal dialysis solutions. Nephron 1995;69:466–471.
17.
Gotloib L, Wajsbrot V, Shostak A, Kushnier R: Acute and long-term changes observed in imprints of mouse mesothelium exposed to glucose-enriched, lactated, buffered dialysis solutions. Nephron 1995;70:466–477.
18.
Gotloib L, Wajsbrot V, Shostak A, Kushnier R: Population analysis of mesothelium in situ and in vivo exposed to bicarbonate-buffered peritoneal dialysis fluid. Nephron 1996;73:219–227.
19.
Gotloib L, Shostak A: Large mesothelial cells in peritoneal dialysis: A sign of degeneration or adaptation? Perit Dial Int 1996;16:118–120.
20.
Efskind L: Experimentelle Untersuchungen über die Biologie des Peritoneums. 1. Die morphologische Reaktion des Peritoneums auf Reize. Oslo, Det Norske Vindenscapss Academii, 1940.
21.
Wieslander AP: Cytotoxicity of peritoneal dialysis fluid: Is it related to glucose breakdown products? Nephrol Dial Transplant 1996;11:958–959.
22.
Breborowicz A, Balaskas E, Oreopoulos GD, Martis L, Serkes K, Oreopoulos DG: In vitro study of the effect of osmotic solutes on the interactions between cells from the peritoneum and peritoneal cavity. Perit Dial Int 1994;14:149–154.
23.
Chaimovitz C, Rapaport J, Konforti J, Dovdevani A: Commercial dialysis fluid causes intracellular acidosis in peritoneal macrophages. J Am Soc Nephrol 1992;4:407–412.
24.
Di Paolo N, Garosi G, Traversari L, Di Paolo M: Mesothelial biocompatibility of peritoneal dialysis solutions. Perit Dial Int 1993;13(suppl 2):109–112.
25.
Topley N, Kaur D, Petersen MM, Jorres A, Williams JD, Faict D, Holmes CJ: In vitro effect of bicarbonate and bicarbonate-lactate buffered peritoneal dialysis solutions on mesothelial and neutrophil function. J Am Soc Nephrol 1996;7:218–224.
26.
Institute of Laboratory Animals Resources: Guide for the Care and Use of Laboratory Animals. National Institutes of Health-DHEW Publication (NIH) 72-73. Washington, Government Printing Office, 1972.
27.
Mitruka BM, Rausley HM, Vadehra DV: Animals for Medical Research: Models for the Study of Human Disease. New York, Wiley & Sons, 1976, p 24.
28.
The UFAW Handbook of the Care and Management of Laboratory Animals. Edinburgh, Churchill-Livingstone, 1972, p 160.
29.
Schwartz D, Flammant R, Lellouch J: L’essai thérapeutique chez l’homme. Paris, Flammarion, 1970, pp 95–106.
30.
Glantz SA: Primer of Biostatistics. New York, McGraw-Hill, 1992, p 348.
31.
Watters WB, Buch RC: Mitotic activity of peritoneum in contact with a regenerative area of peritoneum. Virchows Arch B Cell Pathol 1973;13:48–52.
32.
Topley N, Alobaidi HM, Davies M, Coles GA, Williams JD, Lloyd D: The effect of dialysate on peritoneal phagocyte oxidative metabolism. Kidney Int 1988;34:401–411.
33.
Carlsson J: Microbial aspects of frequent intake of products with high sugar concentrations. Scand J Dent Res 1989;97:110–114.
34.
Nolph KD, Twardowski ZJ, Popovich RP, Rubin J: Equilibrium of peritoneal dialysis solutions during long dwell exchanges. J Lab Clin Med 1979;93:246–256.
35.
Pendergrass W, Angello J, Norwood TH: The relationship between cell size, the activity of DNA polymerase alpha and proliferative activity in human diploid fibroblast-like cell cultures. Exp Gerontol 1989;24:383–393.
36.
Guhe C, Follmann W: Growth and characterization of porcine urinary bladder epithelial cells in vitro. Am J Physiol 1994;266:F298–F308.
37.
Angello JC, Pendergrass WR, Norwood TH, Prothero J: Cell enlargement: One possible mechanism underlying cellular senescence. J Cell Physiol 1989;140:288–294.
38.
Di Paolo N, Garosi G, Petrini G, Traversari L, Rossi P: Peritoneal dialysis solution biocompatibility testing in animals. Perit Dial Int 1995;15(suppl 7):61–70.
39.
Cunningham RS: Studies on absorption from serous cavities. II. The effect of dextrose upon the peritoneal mesothelium. Am J Physiol 1920;53:488–501.
40.
Cunningham RS: The effects of chronic irritation on the morphology of the peritoneal mesothelium. Johns Hopkins Hosp Bull 1924;35:111–115.
41.
Morocutti A, Earle KA, Sethi M, Piras G, Pal K, Richards D, Rodemann P, Viberti G: Premature senescence of skin fibroblasts from insulin-dependent diabetic patients with kidney disease. Kidney Int 1996;50:250–256.
42.
Stout RW: Glucose inhibits replication of cultured human endothelial cells. Diabetologia 1982;23:436–439.
43.
Trachtman H, Futterweit S, Frenner J, Hanon S: Antioxidants reverse the antiproliferative effect of high glucose and advanced glycosylation end products in cultured rat mesangial cells. Biochem Biophys Res Commun 1994;199:346–352.
44.
Sharma K, Ziyadeh FN: Hyperglycemia and diabetic kidney disease: The case for transforming growth factor-beta as a key mediator. Diabetes 1995;44:1139–1146.
45.
Fisher EJ, McLennan SV, Yue DK, Turtle JR: Cell-associated proteoglycans of retinal pericytes and endothelial cells: Modulation by glucose and ascorbic acid. Microvasc Res 1994;48:179–189.
46.
Lorenzi M, Cagliero E, Toledo S: Glucose toxicity for human endothelial cells in culture. Diabetes 1985;34:621–627.
47.
Lorenzi M, Nordberg JA, Toledo S: High glucose prolongs cell-cycle traversal of cultured human endothelial cells. Diabetes 1987;36:1261–1267.
48.
Breborowicz A, Witowski J, Weczorowska K, Martis L, Serkes KD, Oreopoulos DG: Toxicity of free redicals to mesothelial cells and peritoneal membrane. Nephron 1993;65:62–66.
49.
Paterson AJ, Kudlow JE: Regulation of glutamine fructose-6-phosphate amidotransferase gene transcription by epidermal growth factor and glucose. Endocrinology 1995;136:2809–2816.
50.
Kumano K, Manalaysay MT, Hyodo T, Sakai T: Inhibition of peritoneal mesothelial cell growth by glycosylated albumin. Perit Dial Int 1995;15(suppl 1):76.
51.
Martinson E, Wieslander A, Kjellstrand P, Boberg U: Toxicity of heat sterilized peritoneal dialysis fluids is derived from degradation of glucose. ASAIO J 1992;38:M370–M372.
52.
Thorpe SR, Baynes JW: Role of the Maillard reaction in diabetes mellitus and diseases of aging. Drugs Aging 1966;9:69–77.
53.
Siegel LS, Bernlohr RW: Lactate or pyruvate stimulated growth of Novikoff rat hepatoma cells. In Vitro 1979;15:545–554.
54.
Topley N, Mackenzie R, Petersen MM, Beavis MH, Williams D, Thomas N, Faict D, Peluso F, Coles GA, Davies M, Williams JD: In vitro testing of a potentially biocompatible continuous ambulatory peritoneal dialysis fluid. Nephrol Dial Transplant 1991;6:574–581.
55.
Jensen JC, Buresh C, Norton JA: Lactic acidosis increases tumor necrosis factor secretion and transcription in vitro. J Surg Res 1990;49:350–353.
56.
Omar HA, Mohazzab KM, Mortelliti MP, Wolin MS: O2 dependent modulation of calf pulmonary artery tone by lactate: Potential role of H2O2 and cCMP. Am J Physiol 1993;264:L141–L145.
57.
Feriani M, Biasoli S, Borin D, Bragantini L, Brendolani A, Chiaramonte S, Dell’Aguila R, Fabris A, Ronco C, La Greca G: Bicarbonate buffer for CAPD solutions. Trans Am Soc Artif Intern Organs 1985;31:668–672.
58.
Gotloib L, Shostak A, Wajsbrot V: Detrimental effects of peritoneal dialysis solution upon in vivo and in situ exposed mesothelium. Perit Dial Int 1997;17(suppl 2):13–16.
59.
Castro L, Alvarez MN, Radi R: Modulatory role of nitric oxide on superoxide-dependent luminol chemiluminescence. Arch Biochem Biophys 1996;333:179–188.
60.
Sugihara N, Suetsugu T, Furuno K: High susceptibility to paraquat-driven peroxidation of cultured hepatocytes loaded with linolenic acid. J Pharmacol Exp Ther 1995;274:187–193.
61.
Chaturvedi V, Wong B, Newman SL: Oxidative killing of Cryptococcus neoformans by human neutrophils: Evidence that fungal mannitol protects by scavenging reactive oxygen intermediates. J Immunol 1996;156:3836–3840.
62.
Staub F, Mackert B, Kempski O, Peters J, Baethman A: Swelling and death of neuronal cells by lactic acid. J Neurol Sci 1993;119:79–84.
63.
Chan L, Slater J, Hasbargen J, Herndon DN, Veech RL, Wolf S: Neurocardiac toxicity of racemic DL-lactate fluids. Integr Physiol Behav Sci 1994;29:383–394.
64.
Staub F, Baethmann A, Peters J, Kempski O: Effects of lactacidosis on volume and viability of glial cells. Acta Neurochir (Wien) 1990;51(suppl):3–6.
1998
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.